This paper reviews four areas of research into anorexia nervosa (AN) and bulimia nervosa (BN) R esearch into anorexia nervosa (AN) and bulimia nervosa (B.N) is progressing at a rapid rate. Meanwhile, patients with eating disorders continue to present major therapeutic challenges to clinicians. In a review of the progress made in clinical research on AN and BN, Garfinkel and colleagues ( I) described a series of risk factors which may both initiate and perpetuate these chronic disorders and highlighted several serious complications. This paper will provide an update on the issues of diagnosis, comorbidity, treatment and outcome in this rapidly changing field.
quire a reduction to below 85% of expected body weight. Previously, a reduction was required to below 75%. Also, three consecutive months of amenorrhea was added as a criterion for women. These modest changes have done little to alter the definition of anorexia nervosa. Rather, in keeping with psychiatric thinking over the past four decades (2) , AN has been maintained as a distinct psychiatric syndrome.
In the draft proposal of the DSM-IV, AN is subtyped into bulimic and restricter groups, in contrast to the current style of dual diagnosis (3) . Major differences between bulimic and restrictive types of AN have been repeatedly demonstrated (4, 5) , although this distinction does not predict long term outcome (6) . BN itself was not recognized as a distinct syndrome until just over a decade ago (7) . The diagnostic criteria for bulimia, and later, bulimia nervosa, were substantially revised between the DSM-III and the DSM-III-R. The revisions included both a definition of the frequency of binge eating episodes (now at least two episodes per week for at least three months) and a criterion of persistent overconcern about body weight and body shape. This has made the diagnosis of BN much more restrictive. For example, Ben Tovim (8) reported a greater than tenfold reduction in the frequency of BN when the more narrow criteria in the DSM-III-R were applied.
The value of including the criterion of persistent overconcern with weight and shape has been argued elsewhere (9) . This criterion connects BN more closely to the related disorder, AN, while linking the DSM criteria to proposed changes in the ICD-IO. It excludes people who, during a primary depressive illness, overeat but lack excessive concerns about their weight and shape. Concerns were initially expressed about the overlap between people with eating disorders and normal females who share this characteristic. Recent studies using the Eating Disorder Examination, a structured interview, have empirically shown that women with bulimia nervosa have excessive concerns about weight and shape compared with "healthy women" (10) and dieting women (II). There may be value in sharpening this criterion by linking the overriding importance of weight and shape to the regulation of affect. The proposal in the DSM-IV of a distinct "binge eating disorder," (12) characterized by recurrent binge eating in the absence of compensatory features of BN, may increase the homogeneity of each syndrome. For these reasons, we feel that the changes in the diagnostic criteria for BN have been valuable.
Eating Disorders and Comorbidity

Depression
Despite claims to the contrary (13, 14) , AN and BN are not merely variants of affective disorder. Nevertheless, the association between eating disorders and major depression cannot be ignored. This relationship has been reviewed extensively (15) and has important implications for treatment.
Symptoms associated with starvation closely resemble those of major depression. For a substantial group of patients with eating disorders, however, a depressive syndrome either persists or develops after nutritional and weight restoration. Toner and colleagues (6) reported a lifetime prevalence of major depression in over 60% of AN patients as long as ten years after treatment. This finding included individuals who had experienced a complete remission of the eating disorder. There is also evidence of differences in both neuroendocrine and family history between depressed and non depressed patients.
Kennedy and colleagues (I 6) reported significantly lower levels of the hormone melatonin in those patients with eating disorders who had concurrent major depression. Kassett et al (17) reported that a history of depression was much more common in the relatives of BN patients who had concurrent depression. Such observations suggest that a subgroup of patients with eating disorders are vulnerable to depression and, at times, may require treatment with antidepressants for concurrent major depression. The role of antidepressants in BN will be discussed later.
Obsessive Compulsive Disorder
There is also evidence of a relationship between the eating disorders, especially AN, and obsessive compulsive disorder (OCD) (I8). This is based on common symptomatology (19) , family history (20) , neuroendocrine abnormalities (21) , and responses to pharmacotherapy (22) . As is the case with depression, there are several areas of overlap between OCD and eating disorders; yet there are reasons for accepting the distinct qualities of each syndrome. In the eating disorders, the primary symptom -a drive for thinness -is ego-syntonic. In OCD, the symptoms are ego-dystonic. It should also be noted that while more AN patients than expected have premorbid obsessional personality traits (I8), the overlap in symptomatology between patients with AN and OCD may be exaggerated by the effects of starvation.
There are conflicting data with regard to the presence of eating pathology in individuals with OCD. For example, Kasvikis and colleagues (23) and Rasmussen (24) reported that ten percent and 17% of OCD patients, respectively, had an "eating disorder." However, this was not confirmed in a report by Joffe and Swinson (25) , who examined only current eating disorder symptoms using a psychometric screen.
These associations may also be linked to shared disturbances in the serotonin (5-HT) neurotransmitter system (26) . Evidence suggests that a central 5-HT disturbance is associated with several psychiatric disorders, including depression, alcoholism, anxiety, OCD, as well as AN and BN. As a corollary, however, recent studies have shown that changes in diet influence 5-HT functioning -particularly among women (27) .
Furthermore, neuroendocrine provocation tests have been used to evaluate the responses of peripheral hormones believed to be at least partially under central serotonergic control. Blunted prolactin responses to both serotonin precursors -tryptophan and 5 hydroxy-tryptophanand to m-chlorophenylpiperiazine (m-cpp) -a serotonin receptor agonist -have been reported in patients with BN (28, 29) . In a separate, comparative study, Hollander and colleagues (21) demonstrated blunted prolactin and cortisol responses to challenges with m-cpp in both OCD and eating disorder patients. In addition, the antidepressants clomipramine and fluoxetine, recognized as effective drugs in the treatment of OCD (30, 31) , have been advocated in the treatment of both AN (22, 32) and BN (33) .
Personality Disorder
A third area of comorbidity related to AN and BN involves personality disorder (PD). In the DSM-III-R, three PD clusters are recognized: an eccentric or odd group (paranoid, schizoid and schizotypal); an impulsive or dramatic group (borderline, narcissistic, histrionic and antisocial); and an anxious or fearful group (avoidant, dependent, compulsive and passive aggressive).
Impulsiveness is a distinguishing feature of patients with AN who have bulimic features (AN and BN) (4) when compared with a "restricting" (AN) population. Piran and colleagues (34) reported a high rate of impulsive personality disorders among subjects with AN and BN (55% had borderline personality disorder (BPD». In contrast, a high rate of anxious personality disorders was found in the AN group (60% met the criteria for avoidant personality disorder). In addition, using more rigid criteria for BPD, Pope and colleagues (35) reported that only two percent of patients met criteria for this diagnosis.
The lack of stability of the measures of personality disorder has been observed using the Millon Clinical Multiaxial Inventory (MCMI) (36) . This self-report questionnaire was administered before and after treatment to patients in hospital with AN or BN (37) . On eight of the 11 scales, the scores decreased significantly between admission and discharge. Only the score on the compulsive scale did not change: the scores on the narcissistic and histrionic scales actually increased after treatment. Changes in scores on personality disorder scales correlated strongly with changes in measures of general psychopathology, suggesting that, at least in the case of the MCMI, personality disorder diagnoses are influenced by Axis I symptomatology. Nevertheless, there is preliminary evidence that the MCMI has predictive value both for response to treatment (38) and outcome after one year (39) . Thus, it is probably best to evaluate personality disorder diagnoses when the acute symptoms associated with AN or BN have stabilized or are in remission.
Substance Abuse
Patients with BN and those with substance abuse share impulsive self-destructive behaviours which are carried out repetitively, often with a great deal of denial, until physical or social consequences force the individual to seek treatment (40) . Studies of comorbidity have been reported in both directions.
There is evidence of a higher than expected prevalence of drug and alcohol abuse among individuals with BN (41) and their families (17) . Similarly, in a survey of consecutive callers to a cocaine hotline, 22% met the lifetime criteria for BN, seven percent for both AN and BN, and two percent for AN alone (42) . Thirty percent of the women surveyed at an alcohol treatment program (43) had clinically significant elevations in their scores on the Eating Attitudes Test (44) .
Psychological Therapies
Bulimia Nervosa
For patients with BN, most psychological studies have employed cognitive-behavioural (CB) techniques either in groups or on an individual basis, while pharmacological studies have involved primarily antidepressant drugs. In the current generation of trials, direct comparisons of these treatments are being reported (45, 46) .
In general, cognitive-behavioural treatments produce substantial improvements in both eating behaviour (including in episodes of overeating, a reduction in the use of other methods of weight control and in the level of dietary restraint), as well as an 'improvement in attitude about body shape and weight.
Self-monitoring, usually with a daily diary to record food intake, vomiting and other purge behaviour, is a central part of most cognitive-behavioural programs. Other techniques are reducing environmental cues to binge, meal planning, introducing forbidden foods, problem-solving skills, relaxation training and education and cognitive restructuring (47) . In a review of the literature on reported cognitive-behavioural treatments for BN up to 1985, Garner et al (48) estimated that 40% of patients were no longer bingeing by the end of treatment, 30% had a reduction in symptoms of at.least 50%, and the remaining 30% showed little improvement.
In a few studies, the benefits of an intense behavioural approach have been compared with those of standard CB techniques. The former involve exposure to binge foods, with response prevention occurring either before a binge takes place (55) or after the binge but before purging (49, 50) . When Agras and colleagues (50) compared three treatment approaches (self-monitoring, cognitive-behavioural and cognitive-behavioural with response prevention of vomiting) to a wait list control group, there was no added benefit from the combination of CB and response prevention. In fact, fewer BN subjects in the combination treatment group reported abstinence at the end of the study than those who received only CB therapy. Patients who were treated with a combination of cognitive treatment and response prevention of vomiting had greater improvement than patients who received CB therapy alone (51) . However, in some instances, patients who were encouraged to binge and then prevented from vomiting found the treatment to be aversive and repeatedly cancelled sessions (52) . Exposure to binge foods and response prevention of bingeing may be more acceptable to both patients and therapists (49) .
Within this category of therapies, considerable differences in the frequency and intensity of treatment have been reported. In two instances, brief group psychoeducation with minimal intervention has been found to be beneficial to a minority of patients (38, 53) . Using a much more intensive approach, Mitchell and colleagues (44) provided up to 15 hours of weekly of group psychotherapy in the initial stages of a study comparing CB and antidepressant therapies. They found dramatic improvements in the patients treated with intensive group psychotherapy.
Psychodynamic therapies for treating BN have not been well studied. Frommer et al (54) reported on a psychodynamic group approach in which patients experienced a 23% decline in bingeing and a 14.5% reduction in vomiting, which is comparable to the response rates found for groups treated with placebo. Preliminary reports on a comparative study of CB and interpersonal psychotherapy for patients with BN indicate remission rates of about 30% for both groups at the end of the study (55) and a continued cessation of binge eating and purging in approximately 40% of both groups who remained in follow-up after one year (56) . These data suggest that incorporating components of CB therapy in treatment is beneficial, but that many bulimic patients respond to interpersonal therapy as well.
Anorexia Nervosa
In contrast to BN, limited attention has been devoted to psychotherapy trials with AN patients. Hall and Crisp (57) compared "dietary advice" with "combined individual and familial psychotherapy." Both groups of patients received 12 sessions and were evaluated one year later. In general, both groups improved to the same extent, although weight gain was greater in the group that received dietary advice while improvements in social and sexual adjustment scores were higher among the group treated with psychotherapy. Channon and colleagues (58) evaluated the added benefit of cognitive treatment "to directly manipulate dysfunctional thoughts and beliefs" in a comparison of outpatient behavioural therapy (BT) and cognitive-behavioural therapy for AN. Based on the Eating Disorder Inventory (59), there were no significant differences between groups at the end of treatment. However, after six months the group who had received CB therapy were significantly better adjusted on measures of interpersonal distrust and psychosexual functioning. . In the first controlled trial of family therapy for AN and BN, Russell and colleagues (60) compared the impact of family therapy and individual psychotherapy on a group of weight-restored patients during their first year after discharge from hospital. Individuals who had developed the disorder before they were 18 years old, with a duration of less than three years, did significantly better with family therapy. For all other categories, the outcome was equally unfavourable in both the family therapy and individual therapy groups.
There does not yet appear to be a consensus based on data from comparative studies on the most favourable sequence of treatment approaches for people with AN.
Pharmacotherapies
Bulimia Nervosa
Most controlled trials of antidepressants have found a significant reduction in the frequency of behaviours associated with BN (binge episodes, vomiting and other purging activities) over short treatment intervals of six to 16 weeks. Tricyclics, including imipramine (61), desipramine (62) and amitriptyline (63) , have all been studied. Only with amitriptyline did the active drug group fail to improve more than the placebo-treated group. This was related most likely to the administration of "minimal behaviour therapy" to both groups. Monoamine oxidase inhibitors have also produced short term behavioural improvement in people with BN (64, 65) as have several "new generation" antidepressants, including trazodone (66) bupropion (67) and fluoxetine (33) . In general, less attention has been paid to evaluating whether or not these treatments alter patients' beliefs and attitudes toward body shape, weight and eating.
Antidepressant drug treatments appear to be equally effective in treating depressed and non depressed patients with BN, suggesting that the mechanism of action may not be "antidepressant". Instead, direct central effects on neurotransmitter systems (including serotonin and norepinephrine) involved in the regulation of eating may be responsible.
While clinicians are more likely to prescribe antidepressants for patients with BN and concurrent depression, it is also important to consider the use of drug therapy for controlling eating habits, either alone or in combination with other therapies. Goldbloom et al (68) have published a practical review of these therapies.
Combined Drug and Cognitive-Behavioural Therapy
In the Mitchell and Groat (63) study, both BN subjects treated with amitriptyline and those treated with a placebo received adjunctive behaviour therapy. The placebo group experienced more than a 50% reduction in binge eating and vomiting, which the authors attributed to the behaviour therapy. In a comparison study of antidepressant treatment (imipramine) and structured intensive group psychotherapy, Mitchell and colleagues (44) reported no additional benefits from the combination of imipramine and group therapy over group therapy alone, except on the affective symptom scores. The extremely intense and lengthy form of group therapy they used (the subjects met for three hours each night, between two and five times per week during the ten week study) prevents any direct comparison between these results and the results of treatments provided under standard clinical conditions. Agras and colleagues (45) , in a controlled comparison of individual CB therapy alone and in combination with desipramine therapy for either 16 or 24 weeks, reported a clinical benefit from the combined treatments when desipramine was continued for 24 weeks.
There is evidence that both psychotherapies and antidepressant medications have beneficial effects for patients with BN. Since there are no comparative studies of these treatments to determine the optimal sequence of therapies and there are no known predictors of antidepressant responses, we recommend that patients begin with a trial of psychotherapy. However, if there is no symptomatic improvement in six to eight weeks, an antidepressant with low antihistaminic and anticholinergic properties should be added. Clinical studies of antidepressants for the treatment of BN have been 16 weeks or less in duration. There are, therefore, no solid data on the length of time that patients should be treated with medication. Until more definitive evidence is reported we suggest gradually discontinuing the drug after the patient has been symptom-free for six months.
Anorexia Nervosa
In general, pharmacotherapy for AN is limited (69) . Recent open trials of fluoxetine with AN patients (22, 70) justify a double-blind placebo controlled trial. Such a study should evaluate the effects of fluoxetine on AN patients with and without major depression.
Studies of the Outcome of BN and AN
As diagnostic criteria for BN become established, followup studies can be carried out to examine predictors of response to treatment and the natural course of the disorder. Few studies have yielded an outcome as optimistic as that reported by Lacey (71): two-thirds of the subjects had "no bulimic or vomiting episodes at all" one year after treatment. A poorer prognosis is associated with the abuse of alcohol, severe bulimia, and possibly having previously suffered from AN.
Others have reported a more chronic course for BN patients, with periods of remission and relapse. In one study, Swift and colleagues (72) , reporting on a small sample of women with BN at least two years after discharge from hospital, found that 27% were asymptomatic, 40% had an intermediate outcome, and the remaining 33% had a poor outcome with "bingeing or purging on a daily basis." Weight fluctuations and dissatisfaction with their body persisted.
With the completion of long term follow-up studies, other aspects of the course of BN can be evaluated, including its longitudinal relationship with AN, as well as mood and personality disorders. In a large five year study, Herzog (73) traced the course of patients with AN, both AN and BN, and BN at three month intervals. There was considerable crossover among the groups, and those who started out in the "mixed AN and BN" group had the lowest recovery rate. Rosenvinge and Mouland (74) also reported "no subjects who had bulimic symptoms at the time of the first admission displayed such symptoms at follow up several years later, and vice versa." In a ten year follow-up study involving similar groups, Eckert (75) reported that binge eating before the index treatment did not predict outcome, while vomiting and laxative abuse were associated with a poorer outcome. There is also evidence that predictors of outcome may change over time. Sohlberg and colleagues (76) examined the variable "impulsive behaviour" (defined as the sum of binge eating, stealing, alcohol and drug abuse, and suicide attempts) as a predictor of outcome. This proved an important predictor of outcome after two years, but had only weak predicti ve power four to six years later.
The Chronic Patient
The longer a patient suffers from AN or BN; the poorer the outcome of treatment (77) . For patients who have been continuously ill for ten years or more, coercive hospital treatment with overly ambitious goals is rarely helpful and may precipitate depression and suicide (78) . In our experience a more realistic approach to managing this type of patient involves brief, time-limited admissions to hospital to halt continued weight loss or metabolic complications. This should be associated with supportive psychotherapy, either individually or in a group (79) .
Conclusions
Since 1987 significant progress has been made in refining and evaluating approaches to treating bulimia nervosa, but much less attention has been paid to managing the patient with anorexia nervosa. Nevertheless, the overlap between AN and BN, and their relationship to other psychiatric diagnoses, including mood disorder, OCD and personality disorder, has received considerable attention. Early indications from outcome studies, involving all categories of AN and BN patients, suggest considerable "switching" between these conditions, particularly from AN to BN. A need exists for renewed interest in treatment approaches to the challenges presented by people with AN. 
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